Alpha 1 Antitrypsin Deficiency Treatment Market by Treatment , End-user and Route of Administration - Global Industry Analysis And Forecast To 2027
Published On : August 2018 Pages : 180 Category: Pharmaceuticals Report Code : HC081157
Industry Outlook and Trend Analysis
Alpha-1 Antitrypsin is a type of glycoprotein that is created in liver, which has a function of preventing renin, Hageman factor, neutral proteases of neutrophils, elastase, etc. If the percentage of Alpha-1 Antitrypsin decreases in the blood stream then Alpha-1 Antitrypsin deficiency (AATD) is caused. AATD causes various disorders like; skin infections, liver disorders and respiratory problems. It is hereditary diseases passed from parents to their children. The Alpha-1 Antitrypsin Deficiency Treatment Market is rising for the due to awareness in the people about the disease.
Treatment Outlook and Trend Analysis
The treatment part of Alpha-1 Antitrypsin Deficiency is divided into; Oxygen Therapy, Corticosteroids, Bronchodilators and Augmentation Therapy. Augmentation therapy is leading the market due to the sub-segments like; Zemaira/Respreeza, Glassia, Prolastin and Aralast, playing important role in the treatment and are predicted to hold the position in the forecasted period.
Route of Administration Outlook and Trend Analysis
On the basis of drugs to be administered to the patient for treatment the market is divided into; drug administration through parenteral route, drug administration through Inhalation route and drug administration through oral route. The market of drugs administered through parenteral route is more than that administered through inhalation. Administration of drug through parental route is easy and more helpful as it prevents the children from getting affected by this deficiency during birth.
Regional Outlook and Trend Analysis
Geographically, the market is segmented into Europe, North America, Asia Pacific, Latin America, Middle East and Africa. North American region is seen lead the global Alpha-1 Antitrypsin Deficiency Treatment Market in recent years but its leading position is seen dropping till the end of projected period. European region is projected of leading the market considered to other regions.
Competitive Insights
Firstly the market is divided globally, also the competition between vendors present in the market is leading to growth of Alpha-1 Antitrypsin Drugs Market. The competition has led to tie-ups or overtaking of small vendor companies by bigger vendor companies, so it’s possible to acquire a large market. The leading players of this market are; Grifols, Teva Pharmaceutical Industries Ltd., Shire plc, Pfizer Inc., Kamada Ltd., AstraZeneca, Boehringer Ingelheim GmbH, GlaxoSmithKline Plc., CSL Behring and LFB Biomedicaments.
The Alpha-1 Antitrypsin Deficiency Treatment Market is segmented as follows-
By Treatment:
- Oxygen Therapy
- Corticosteroids
- Bronchodilators
- Augmentation Therapy
By Route of Administration:
- Parenteral
- Inhalation
- Oral
By End User:
- Hospitals,
- Pharmacies
- Specialty Clinics
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Alpha 1 Antitrypsin Deficiency Treatment Market, By Treatment, Estimates and Forecast, 2017-2027 ($Million)
o Oxygen Therapy
o Corticosteroids
o Bronchodilators
o Augmentation Therapy
· Alpha 1 Antitrypsin Deficiency Treatment Market, By Route of Administration, Estimates and Forecast, 2017-2027 ($Million)
o Parenteral
o Inhalation
o Oral
· Alpha 1 Antitrypsin Deficiency Treatment Market, By End User, Estimates and Forecast, 2017-2027 ($Million)
o Hospitals,
o Pharmacies
o Specialty Clinics
· Alpha 1 Antitrypsin Deficiency Treatment Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Alpha 1 Antitrypsin Deficiency Treatment Market, By Country
o U.S. Alpha 1 Antitrypsin Deficiency Treatment Market
o Canada Alpha 1 Antitrypsin Deficiency Treatment Market
o Mexico Alpha 1 Antitrypsin Deficiency Treatment Market
o Europe
§ Europe Alpha 1 Antitrypsin Deficiency Treatment Market, By Country
o Germany Alpha 1 Antitrypsin Deficiency Treatment Market
o UK Alpha 1 Antitrypsin Deficiency Treatment Market
o France Alpha 1 Antitrypsin Deficiency Treatment Market
o Russia Alpha 1 Antitrypsin Deficiency Treatment Market
o Italy Alpha 1 Antitrypsin Deficiency Treatment Market
o Rest of Europe Alpha 1 Antitrypsin Deficiency Treatment Market
o Asia-Pacific
§ Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market, By Country
o China Alpha 1 Antitrypsin Deficiency Treatment Market
o Japan Alpha 1 Antitrypsin Deficiency Treatment Market
o South Korea Alpha 1 Antitrypsin Deficiency Treatment Market
o India Alpha 1 Antitrypsin Deficiency Treatment Market
o Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Market
o Rest of Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market
o South America
§ South America Alpha 1 Antitrypsin Deficiency Treatment Market
o Brazil Alpha 1 Antitrypsin Deficiency Treatment Market
o Argentina Alpha 1 Antitrypsin Deficiency Treatment Market
o Columbia Alpha 1 Antitrypsin Deficiency Treatment Market
o Rest of South America Alpha 1 Antitrypsin Deficiency Treatment Market
o Middle East and Africa
§ Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market
o Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Market
o UAE Alpha 1 Antitrypsin Deficiency Treatment Market
o Egypt Alpha 1 Antitrypsin Deficiency Treatment Market
o Nigeria Alpha 1 Antitrypsin Deficiency Treatment Market
o South Africa Alpha 1 Antitrypsin Deficiency Treatment Market
o Rest of MEA Alpha 1 Antitrypsin Deficiency Treatment Market
Table of Contents
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Alpha 1 Antitrypsin Deficiency Treatment Market, By Treatment
5.1. Introduction
5.2. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue and Market Share by Treatment (2017-2027)
5.2.1. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue and Revenue Share by Treatment (2017-2027)
5.3. Oxygen Therapy
5.3.1. Global Oxygen Therapy Revenue and Growth Rate (2017-2027)
5.4. Corticosteroids
5.4.1. Global Corticosteroids Revenue and Growth Rate (2017-2027)
5.5. Bronchodilators
5.5.1. Global Bronchodilators Revenue and Growth Rate (2017-2027)
5.6. Augmentation Therapy
5.6.1. Global Augmentation Therapy Revenue and Growth Rate (2017-2027)
6. Alpha 1 Antitrypsin Deficiency Treatment Market, By Route Of Administration
6.1. Introduction
6.2. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue and Market Share by Route Of Administration (2017-2027)
6.2.1. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue and Revenue Share by Route Of Administration (2017-2027)
6.3. Parenteral
6.3.1. Global Parenteral Revenue and Growth Rate (2017-2027)
6.4. Inhalation
6.4.1. Global Inhalation Revenue and Growth Rate (2017-2027)
6.5. Oral
6.5.1. Global Oral Revenue and Growth Rate (2017-2027)
7. Alpha 1 Antitrypsin Deficiency Treatment Market, By End User
7.1. Introduction
7.2. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue and Market Share by End User (2017-2027)
7.2.1. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue and Revenue Share by End User (2017-2027)
7.3. Hospitals
7.3.1. Global Hospitals Revenue and Growth Rate (2017-2027)
7.4. Pharmacies
7.4.1. Global Pharmacies Revenue and Growth Rate (2017-2027)
7.5. Specialty Clinics
7.5.1. Global Specialty Clinics Revenue and Growth Rate (2017-2027)
8. Alpha 1 Antitrypsin Deficiency Treatment Market, By Region
8.1. Introduction
8.2. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue and Market Share by Regions
8.2.1. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Regions (2017-2027)
8.3. North America Alpha 1 Antitrypsin Deficiency Treatment by Countries
8.3.1. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2027)
8.3.2. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) by Countries (2017-2027)
8.3.3. United States
8.3.3.1. United States Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.4. Canada
8.3.4.1. Canada Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.3.5. Mexico
8.3.5.1. Mexico Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.4. Europe Alpha 1 Antitrypsin Deficiency Treatment by Countries
8.4.1. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2027)
8.4.2. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) by Countries (2017-2027)
8.4.3. Germany
8.4.3.1. Germany Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.4. France
8.4.4.1. France Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.5. UK
8.4.5.1. UK Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.6. Russia
8.4.6.1. Russia Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.7. Italy
8.4.7.1. Italy Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.4.8. Rest of Europe
8.4.8.1. Rest of Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.5. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment by Countries
8.5.1. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2027)
8.5.2. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) by Countries (2017-2027)
8.5.3. China
8.5.3.1. China Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.4. Japan
8.5.4.1. Japan Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.5. Korea
8.5.5.1. Korea Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.6. India
8.5.6.1. India Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.7. Southeast Asia
8.5.7.1. Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.5.8. Rest of Asia-Pacific
8.5.8.1. Rest of Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.6. South America Alpha 1 Antitrypsin Deficiency Treatment by Countries
8.6.1. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2027)
8.6.2. South America Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) by Countries (2017-2027)
8.6.3. Brazil
8.6.3.1. Brazil Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.4. Argentina
8.6.4.1. Argentina Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.5. Columbia
8.6.5.1. Columbia Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.6.6. Rest of South America
8.6.6.1. Rest of South America Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.7. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment by Countries
8.7.1. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2027)
8.7.2. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) by Countries (2017-2027)
8.7.3. Saudi Arabia
8.7.3.1. Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.4. United Arab Emirates
8.7.4.1. United Arab Emirates Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.5. Egypt
8.7.5.1. Egypt Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.6. Nigeria
8.7.6.1. Nigeria Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.7. South Africa
8.7.7.1. South Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.8. Turkey
8.7.8.1. Turkey Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
8.7.9. Rest of Middle East and Africa
8.7.9.1. Rest of Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
9. Company Profiles
9.1. Grifols
9.1.1. Business Overview
9.1.2. Service Portfolio
9.1.3. Strategic Developments
9.1.4. Financial Overview
9.2. Teva Pharmaceutical Industries Ltd.
9.2.1. Business Overview
9.2.2. Service Portfolio
9.2.3. Strategic Developments
9.2.4. Financial Overview
9.3. Shire plc, Pfizer Inc.
9.3.1. Business Overview
9.3.2. Service Portfolio
9.3.3. Strategic Developments
9.3.4. Financial Overview
9.4. Kamada Ltd.
9.4.1. Business Overview
9.4.2. Service Portfolio
9.4.3. Strategic Developments
9.4.4. Financial Overview
9.5. AstraZeneca
9.5.1. Business Overview
9.5.2. Service Portfolio
9.5.3. Strategic Developments
9.5.4. Financial Overview
9.6. Boehringer Ingelheim GmbH
9.6.1. Business Overview
9.6.2. Service Portfolio
9.6.3. Strategic Developments
9.6.4. Financial Overview
9.7. GlaxoSmithKline Plc.
9.7.1. Business Overview
9.7.2. Service Portfolio
9.7.3. Strategic Developments
9.7.4. Financial Overview
9.8. CSL Behring
9.8.1. Business Overview
9.8.2. Service Portfolio
9.8.3. Strategic Developments
9.8.4. Financial Overview
9.9. LFB Biomedicaments
9.9.1. Business Overview
9.9.2. Service Portfolio
9.9.3. Strategic Developments
9.9.4. Financial Overview
10. Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.1. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2027)
10.2. Alpha 1 Antitrypsin Deficiency Treatment Market Forecast by Regions (2017-2027)
10.2.1. North America Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.2.1.1. United States Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.2.1.2. Canada Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.2.1.3. Mexico Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.2.2. Europe Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.2.2.1. Germany Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.2.2.2. France Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.2.2.3. UK Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.2.2.4. Russia Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.2.2.5. Italy Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.2.2.6. Rest of Europe Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.2.3. Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.2.3.1. China Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.2.3.2. Japan Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.2.3.3. Korea Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.2.3.4. India Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.2.3.5. Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.2.3.6. Rest of Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.2.4. South America Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.2.4.1. Brazil Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.2.4.2. Argentina Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.2.4.3. Columbia Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.2.4.4. Rest of South America Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.2.5. Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.2.5.1. Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.2.5.2. United Arab Emirates Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.2.5.3. Egypt Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.2.5.4. Nigeria Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.2.5.5. South Africa Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.2.5.6. Turkey Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.2.5.7. Rest of Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2017-2027)
10.3. Alpha 1 Antitrypsin Deficiency Treatment Market Forecast by Treatment (2017-2027)
10.3.1. Alpha 1 Antitrypsin Deficiency Treatment Forecast by Treatment (2017-2027)
10.3.2. Alpha 1 Antitrypsin Deficiency Treatment Market Share Forecast by Treatment (2017-2027)
10.4. Alpha 1 Antitrypsin Deficiency Treatment Market Forecast by Route Of Administration (2017-2027)
10.4.1. Alpha 1 Antitrypsin Deficiency Treatment Forecast by Route Of Administration (2017-2027)
10.4.2. Alpha 1 Antitrypsin Deficiency Treatment Market Share Forecast by Route Of Administration (2017-2027)
10.5. Alpha 1 Antitrypsin Deficiency Treatment Market Forecast by End User (2017-2027)
10.5.1. Alpha 1 Antitrypsin Deficiency Treatment Forecast by End User (2017-2027)
10.5.2. Alpha 1 Antitrypsin Deficiency Treatment Market Share Forecast by End User (2017-2027)
List of Tables
Figure United States Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Alpha 1 Antitrypsin Deficiency Treatment Revenue and Revenue Share by Treatment (2017-2018)
Figure Global Oxygen Therapy Revenue and Growth Rate (2017-2018)
Figure Global Corticosteroids Revenue and Growth Rate (2017-2018)
Figure Global Bronchodilators Revenue and Growth Rate (2017-2018)
Figure Global Augmentation Therapy Revenue and Growth Rate (2017-2018)
Table Global Alpha 1 Antitrypsin Deficiency Treatment Revenue and Revenue Share by Route Of Administration (2017-2018)
Figure Global Parenteral Revenue and Growth Rate (2017-2018)
Figure Global Inhalation Revenue and Growth Rate (2017-2018)
Figure Global Oral Revenue and Growth Rate (2017-2018)
Table Global Alpha 1 Antitrypsin Deficiency Treatment Revenue and Revenue Share by End User (2017-2018)
Figure Global Hospitals Revenue and Growth Rate (2017-2018)
Figure Global Pharmacies Revenue and Growth Rate (2017-2018)
Figure Global Specialty Clinics Revenue and Growth Rate (2017-2018)
Table Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Regions (2017-2018)
Figure North America Alpha 1 Antitrypsin Deficiency Treatment Growth Rate (2017-2018)
Figure North America Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2018)
Figure North America Alpha 1 Antitrypsin Deficiency Treatment by Countries (2017-2018)
Figure North America Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) by Countries (2017-2018)
Figure United States Alpha 1 Antitrypsin Deficiency Treatment Growth Rate (2017-2018)
Figure United States Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Alpha 1 Antitrypsin Deficiency Treatment Growth Rate (2017-2018)
Figure Canada Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Alpha 1 Antitrypsin Deficiency Treatment Growth Rate (2017-2018)
Figure Mexico Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Alpha 1 Antitrypsin Deficiency Treatment Growth Rate (2017-2018)
Figure Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2018)
Figure Europe Alpha 1 Antitrypsin Deficiency Treatment by Countries (2017-2018)
Figure Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) by Countries (2017-2018)
Figure Germany Alpha 1 Antitrypsin Deficiency Treatment Growth Rate (2017-2018)
Figure Germany Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Alpha 1 Antitrypsin Deficiency Treatment Growth Rate (2017-2018)
Figure France Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Alpha 1 Antitrypsin Deficiency Treatment Growth Rate (2017-2018)
Figure UK Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Alpha 1 Antitrypsin Deficiency Treatment Growth Rate (2017-2018)
Figure Russia Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Alpha 1 Antitrypsin Deficiency Treatment Growth Rate (2017-2018)
Figure Italy Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Alpha 1 Antitrypsin Deficiency Treatment Growth Rate (2017-2018)
Figure Rest of Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Growth Rate (2017-2018)
Figure Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment by Countries (2017-2018)
Figure Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) by Countries (2017-2018)
Figure China Alpha 1 Antitrypsin Deficiency Treatment Growth Rate (2017-2018)
Figure China Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Alpha 1 Antitrypsin Deficiency Treatment Growth Rate (2017-2018)
Figure Japan Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Alpha 1 Antitrypsin Deficiency Treatment Growth Rate (2017-2018)
Figure Korea Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Alpha 1 Antitrypsin Deficiency Treatment Growth Rate (2017-2018)
Figure India Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Growth Rate (2017-2018)
Figure Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Alpha 1 Antitrypsin Deficiency Treatment Growth Rate (2017-2018)
Figure South America Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2018)
Figure South America Alpha 1 Antitrypsin Deficiency Treatment by Countries (2017-2018)
Figure South America Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Alpha 1 Antitrypsin Deficiency Treatment Growth Rate (2017-2018)
Figure Brazil Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Alpha 1 Antitrypsin Deficiency Treatment Growth Rate (2017-2018)
Figure Argentina Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Alpha 1 Antitrypsin Deficiency Treatment Growth Rate (2017-2018)
Figure Columbia Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Alpha 1 Antitrypsin Deficiency Treatment Growth Rate (2017-2018)
Figure Rest of South America Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Growth Rate (2017-2018)
Figure Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment by Countries (2017-2018)
Figure Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Growth Rate (2017-2018)
Figure Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Alpha 1 Antitrypsin Deficiency Treatment Growth Rate (2017-2018)
Figure United Arab Emirates Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Alpha 1 Antitrypsin Deficiency Treatment Growth Rate (2017-2018)
Figure Egypt Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Alpha 1 Antitrypsin Deficiency Treatment Growth Rate (2017-2018)
Figure Nigeria Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Alpha 1 Antitrypsin Deficiency Treatment Growth Rate (2017-2018)
Figure South Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Alpha 1 Antitrypsin Deficiency Treatment Growth Rate (2017-2018)
Figure Turkey Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2017-2018)
Table Grifols Alpha 1 Antitrypsin Deficiency Treatment Financial Overview
Table Teva Pharmaceutical Industries Ltd. Alpha 1 Antitrypsin Deficiency Treatment Financial Overview
Table Shire plc, Pfizer Inc. Alpha 1 Antitrypsin Deficiency Treatment Financial Overview
Table Kamada Ltd. Alpha 1 Antitrypsin Deficiency Treatment Financial Overview
Table AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Financial Overview
Table Boehringer Ingelheim GmbH Alpha 1 Antitrypsin Deficiency Treatment Financial Overview
Table GlaxoSmithKline Plc. Alpha 1 Antitrypsin Deficiency Treatment Financial Overview
Table CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Financial Overview
Table LFB Biomedicaments Alpha 1 Antitrypsin Deficiency Treatment Financial Overview
Figure Global Alpha 1 Antitrypsin Deficiency Treatment Revenue (Millions USD) and Growth Rate (2018-2025)
Table Alpha 1 Antitrypsin Deficiency Treatment Market Forecast by Regions (2018-2025)
Figure North America Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2018-2025)
Figure United States Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2018-2025)
Figure Canada Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2018-2025)
Figure Mexico Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2018-2025)
Figure Europe Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2018-2025)
Figure Germany Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2018-2025)
Figure France Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2018-2025)
Figure UK Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2018-2025)
Figure Russia Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2018-2025)
Figure Italy Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2018-2025)
Figure Rest of Europe Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2018-2025)
Figure Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2018-2025)
Figure China Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2018-2025)
Figure Japan Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2018-2025)
Figure Korea Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2018-2025)
Figure India Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2018-2025)
Figure Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2018-2025)
Figure South America Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2018-2025)
Figure Brazil Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2018-2025)
Figure Argentina Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2018-2025)
Figure Columbia Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2018-2025)
Figure Rest of South America Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2018-2025)
Figure Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2018-2025)
Figure Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2018-2025)
Figure United Arab Emirates Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2018-2025)
Figure Egypt Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2018-2025)
Figure Nigeria Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2018-2025)
Figure South Africa Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2018-2025)
Figure Turkey Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Alpha 1 Antitrypsin Deficiency Treatment Market Forecast (2018-2025)
Figure Global Alpha 1 Antitrypsin Deficiency Treatment Forecast by Treatment (2018-2025)
Figure Global Alpha 1 Antitrypsin Deficiency Treatment Market Share Forecast by Treatment (2018-2025)
Figure Global Alpha 1 Antitrypsin Deficiency Treatment Forecast by Treatment (2018-2025)
Figure Global Alpha 1 Antitrypsin Deficiency Treatment Forecast by Route Of Administration (2018-2025)
Figure Global Alpha 1 Antitrypsin Deficiency Treatment Market Share Forecast by Route Of Administration (2018-2025)
Figure Global Alpha 1 Antitrypsin Deficiency Treatment Forecast by Route Of Administration (2018-2025)
Figure Global Alpha 1 Antitrypsin Deficiency Treatment Forecast by End User (2018-2025)
Figure Global Alpha 1 Antitrypsin Deficiency Treatment Market Share Forecast by End User (2018-2025)
Figure Global Alpha 1 Antitrypsin Deficiency Treatment Forecast by End User (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|